← Leaderboards
Samuel Waxman
Mount Sinai School Of Medicine Of Nyu
$3,574,119
Attributed
$3,574,119
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $338.4K · FY2011–15$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$3,574,119 · 3
By mechanism
R01$3,574,119 · 3
Top collaborators
No co-investigators on record.
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Lu-Hai Wang$3,714,929
- Michael J Ross$6,839,251
- Andrew M Chan$3,971,556
- Ting-Chi Lu$210,723
Others in their field
Top investigators on “Transfection”
- David Heimbrook · Leidos Biomedical Research, Inc.$94,306,630
- Richard M Myers · Hudson-Alpha Institute For Biotechnology$39,277,975
- Barton F Haynes · Duke University$19,824,751
- William W Hauswirth · University Of Florida$19,491,817
- Michael P Snyder · Yale University$14,582,826
- Larry Arthur$12,814,310
Research focus
TransfectionTranscription FactorPhenotypeDifferentiation And GrowthAgonistDesignComplexCell LineAfrican AmericanCombinatorialBinding (Molecular Function)BiologicalAmino AcidsAffectBreastAnimal ModelBreast Cancer CellCell DeathBreast Cancer ModelBreast Cancer TreatmentChemotherapeutic AgentChromatinCationic Antimicrobial Protein Cap 37Cdh1 Gene
Grant awards (11)
Targeted epigenetic therapy of triple-negative breast cancer$326,190
R01 · FY2015 · CA · contact PI
Targeted epigenetic therapy of triple-negative breast cancer$316,404
R01 · FY2014 · CA · contact PI
Targeted epigenetic therapy of triple-negative breast cancer$306,619
R01 · FY2013 · CA · contact PI
Targeted epigenetic therapy of triple-negative breast cancer$326,190
R01 · FY2012 · CA · contact PI
Targeted epigenetic therapy of triple-negative breast cancer$338,373
R01 · FY2011 · CA · contact PI
ARSENIC TRIOXIDE TREATMENT OF LYMPHOPROLIFERATIVE DISORD$322,262
R01 · FY2003 · CA
NOVEL GENE REARRANGED WITH THE RAR ALPHA LOCUS$341,022
R01 · FY2002 · CA
ARSENIC TRIOXIDE TREATMENT OF LYMPHOPROLIFERATIVE DISORD$322,262
R01 · FY2002 · CA
NOVEL GENE REARRANGED WITH THE RAR ALPHA LOCUS$331,090
R01 · FY2001 · CA
ARSENIC TRIOXIDE TREATMENT OF LYMPHOPROLIFERATIVE DISORD$322,262
R01 · FY2001 · CA
NOVEL GENE REARRANGED WITH THE RAR ALPHA LOCUS$321,445
R01 · FY2000 · CA